Compendia Bioscience, Inc. is dedicated to gathering the world's high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to ultimately improve the lives of patients.

Oncomine 4.3 is now available!

Oncomine 4.3 provides major data improvements that facilitate identification, interpretation and communication of results.

Gene level DNA copy number results: Easily differentiate large genomic regions of change from localized aberrations
Ability to infer fold change differences for mRNA and DNA data: Filter results to only those with biological and statistical significance
New DNA datasets: Amplification and deletion results across 3,490 cell lines and tumors

These new capabilities provide significant improvements in the assessment of cancer targets, prioritization of findings and the communication of results to your research teams.

Compendia Bioscience's flagship product, Oncomine™, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of success.

Compendia provides product offerings for both research (non-profit) and commercial organizations.

11–14 JUL 2010
AACR Translational Cancer Medicine - USA
San Francisco, CA

OncoPredictor: An integrative genomics platform to systematically predict responsive tumor populations from in vitro drug response data

POSTER SESSION B: Dr. Daniel Rhodes, Chief Executive Officer, Compendia Bioscience

CONFERENCE SPONSOR

Show Site